The University of Texas MD Anderson Cancer Center Oct 22 2025 Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. These findings, which include more than 1,000 patients treated between Aug. 2019 and Aug. 2023, were presented today at the 2025 European Society for

Tag-uri: Coronavirus